Amgen has opened an era of 100 billion won in the osteoporosis treatment market. Sales of the two products are increasing rapidly as sequential treatments leading to Evenity-Prolia are being put forward. According to IQVIA, a pharmaceutical research institute, sales of Amgen's osteoporosis treatment, Denosumab, stood at 92.1 billion won last year, up 22.7% from 75.1 billion won a year earlier. Sales of another treatment, Evenity, increased 220.3% from 3.8 billion won in 2020 to 12.3 billion won last year. The total sales of the two products amounted to 104.4 billion won.

Amgen introduced Prolia in Korea through GSK in 2014 and has been devoted to the osteoporosis treatment market by recovering its copyr